The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilars: Still Waiting for Promise to Materialize

Biosimilars: Still Waiting for Promise to Materialize

January 17, 2018 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Distinctions, Equivalencies
A replica of a biologic agent, which has not undergone regulatory review according to a defined pathway for assessing biosimilars, is called a bio-mimic—not a biosimilar. Because biosimilars are not exact duplicates of their reference products—unlike small-molecule generic drugs—biosimilars should not be considered generic drugs, Dr. Kay said.

You Might Also Like
  • The Science Behind Biosimilars
  • Biosimilars: How Do They Affect Patient Care & Safety?
  • Biosimilars to Raise Unique Questions
Explore This Issue
February 2018

The Biologics Price Competition and Innovation Act of 2009 amended federal statutes to create an abbreviated licensure pathway for biological products shown to be biosimilar or interchangeable. Although the concept of interchangeability has generated concerns among physicians, no biosimilar has yet been approved as interchangeable with its reference product. A draft FDA guidance document on interchangeability was released for comment in January 2017, offering the FDA’s current thinking on the topic.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Three biologic agents used to treat inflammatory diseases, infliximab, etanercept and adalimumab, now have biosimilars approved by the FDA. Dr. Kay said that uptake of biosimilars is off to a slow start in the U.S. market compared with that in the EU, where biosimilars have already generated significant cost savings since the European Medicines Agency approved its first infliximab biosimilar in 2013.

Biosimilars are expected to be as effective and as safe as, and considerably less expensive than, their reference products. Thus, biosimilars have the potential to improve access for rheumatology patients because the drugs are cheaper for patients. However, in the U.S., the actual prices of biosimilars have not necessarily been lower than that of their reference products, Dr. Kay said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In fact, another speaker, Joseph Huffstutter, MD, a rheumatologist in private practice in Chattanooga, Tenn., said that no one has yet used biosimilars in a rheumatology practice in the U.S.

The availability of biosimilars presents a new paradigm for the treatment of rheumatologic diseases, Dr. Kay said. However, healthcare professionals and patients must understand the process by which biosimilars are compared with their reference products and accept an abbreviated clinical development program that does not require clinical trials in each indication for which approval is sought.

“Practice protocols are where the rubber meets the road,” said Dr. Huffstutter. These protocols will be shaped by insurance requirements, state laws and differences in the types of practice settings.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“How do your patients feel about biosimilars?” Dr. Huffstutter asked. “Are there real, considerable cost savings to be realized from the use of biosimilars and that accrue to the patient? If it isn’t considerably cheaper to the patient, and safe, then there’s no value or reason to use it. The whole discussion today is about cost—not about developing better therapeutic tools.”

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Meeting Reports Tagged With: 2017 ACR/ARHP Annual Meeting, ACR/ARHP Annual Meeting, Biologics & Biosimilars, biosimilar, drug pricing, Drug Updates, interchangeabilityIssue: February 2018

You Might Also Like:
  • The Science Behind Biosimilars
  • Biosimilars: How Do They Affect Patient Care & Safety?
  • Biosimilars to Raise Unique Questions
  • Biosimilars Great Debate: To Switch or Not?

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.